Division of Gastroenterology, Hepatology and Nutrition, McGovern Medical School, 6431 Fannin, MSB1.150, Houston, TX, 77030, USA.
Division of Gastroenterology, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon.
Dig Dis Sci. 2021 Aug;66(8):2786-2794. doi: 10.1007/s10620-020-06564-0. Epub 2020 Aug 27.
A single-procedure session combining EUS and ERCP (EUS/ERCP) for tissue diagnosis and biliary decompression for pancreatic duct adenocarcinoma (PDAC) is technically feasible. While EUS/ERCP may offer expedience and convenience over an approach of separate procedures sessions, the technical success and risk for complications of a combined approach is unclear.
Compare the effectiveness and safety of EUS/ERCP versus separate session approaches for PDAC.
Study patients (2010-2015) were identified within our ERCP database. Patients were analyzed in three groups based on approach: Group A: Single-session EUS-FNA and ERCP (EUS/ERCP), Group B: EUS-FNA followed by separate, subsequent ERCP (EUS then ERCP), and Group C: ERCP with/without separate EUS (ERCP ± EUS). Rates of technical success, number of procedures, complications, and time to initiation of PDAC therapies were compared between groups.
Two hundred patients met study criteria. EUS/ERCP approach (Group A) had a longer index procedure duration (median 66 min, p = 0.023). No differences were observed between Group A versus sequential procedure approaches (Groups B and C) for complications (p = 0.109) and success of EUS-FNA (p = 0.711) and ERCP (p = 0.109). Subgroup analysis (> 2 months of follow-up, not referred to hospice, n = 126) was performed. No differences were observed for stent failure (p = 0.307) or need for subsequent procedures (p = 0.220). EUS/ERCP (Group A) was associated with a shorter time to initiation of PDAC therapies (mean, 25.2 vs 42.7 days, p = 0.046).
EUS/ERCP approach has comparable rates of success and complications compared to separate, sequential approaches. An EUS/ERCP approach equates to shorter time interval to initiation of PDAC therapies.
对于胰腺导管腺癌 (PDAC) 患者,EUS 和 ERCP 联合应用于一次手术过程中,既能进行组织诊断,又能进行胆道减压,这种方法在技术上是可行的。虽然与分别进行多次手术相比,EUS/ERCP 可能更快捷、方便,但目前尚不清楚联合应用的技术成功率和并发症风险。
比较 EUS/ERCP 与分别进行手术的方法治疗 PDAC 的效果和安全性。
我们对 2010 年至 2015 年期间在我院接受 ERCP 治疗的患者进行了回顾性研究。患者根据治疗方法分为三组:A 组:单次 EUS-FNA 和 ERCP(EUS/ERCP);B 组:EUS-FNA 后再行单独的后续 ERCP(EUS 后 ERCP);C 组:ERCP 联合/不联合单独 EUS(ERCP±EUS)。比较三组间技术成功率、手术次数、并发症发生率和 PDAC 治疗开始时间的差异。
共有 200 例患者符合研究标准。EUS/ERCP 组(A 组)的操作时间更长(中位数为 66 分钟,p=0.023)。A 组与序贯操作组(B 组和 C 组)在并发症发生率(p=0.109)和 EUS-FNA 成功率(p=0.711)和 ERCP 成功率(p=0.109)方面无差异。进行了亚组分析(随访时间>2 个月,未转至临终关怀,n=126)。支架失败率(p=0.307)或后续治疗需求(p=0.220)无差异。EUS/ERCP 组(A 组)的 PDAC 治疗开始时间更短(平均为 25.2 天 vs 42.7 天,p=0.046)。
与分别进行的序贯操作相比,EUS/ERCP 方法的成功率和并发症发生率相当。EUS/ERCP 方法能更快速地开始 PDAC 治疗。